Alnylam Pharmaceuticals, Inc. (BMV:ALNY)
Mexico · Delayed Price · Currency is MXN 8,380.00
-180.00 (-2.10%)
At close: Sep 2, 2025
Alnylam Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | -319.09 | -278.16 | -440.24 | -1,131 | -852.82 | -858.28 | Upgrade |
Depreciation & Amortization | 56.5 | 56.67 | 54.05 | 44.47 | 89.69 | 74.44 | Upgrade |
Stock-Based Compensation | 305.84 | 272.08 | 221.68 | 230.65 | 165.72 | 139.87 | Upgrade |
Other Adjustments | 175.45 | 155.18 | 211.4 | 307.15 | 118.54 | 41.71 | Upgrade |
Change in Receivables | -240.95 | -86.55 | -87.94 | -45.6 | -101.8 | -56.24 | Upgrade |
Changes in Inventories | 24.13 | 13.59 | 18.37 | -34.14 | -26.42 | -35.43 | Upgrade |
Changes in Accounts Payable | 47.9 | 91.09 | 80.84 | 191.77 | 88.24 | 143.73 | Upgrade |
Changes in Unearned Revenue | -56.34 | -235.45 | 55.02 | -65.91 | -50.4 | -43.97 | Upgrade |
Changes in Other Operating Activities | -8.99 | 3.23 | -9.03 | -38.51 | -72.45 | -20.81 | Upgrade |
Operating Cash Flow | -15.54 | -8.31 | 104.16 | -541.27 | -641.69 | -614.96 | Upgrade |
Capital Expenditures | -36.55 | -34.28 | -62.21 | -72.06 | -76.37 | -70.36 | Upgrade |
Purchases of Investments | -1,778 | -1,712 | -1,882 | -2,075 | -1,698 | -2,052 | Upgrade |
Proceeds from Sale of Investments | 1,723 | 1,630 | 1,612 | 2,322 | 1,506 | 1,692 | Upgrade |
Other Investing Activities | - | -0.12 | -4.44 | -4.69 | -4.2 | -5.3 | Upgrade |
Investing Cash Flow | -110.77 | -116.84 | -336.35 | 169.35 | -273.3 | -435.52 | Upgrade |
Long-Term Debt Issued | - | - | - | 1,016 | 500 | 200 | Upgrade |
Long-Term Debt Repaid | - | - | - | -762.11 | - | - | Upgrade |
Net Long-Term Debt Issued (Repaid) | - | - | - | 254 | 500 | 200 | Upgrade |
Issuance of Common Stock | 274.9 | 302.95 | 147.46 | 259.36 | 246.27 | 299.98 | Upgrade |
Net Common Stock Issued (Repurchased) | 274.9 | 302.95 | 147.46 | 259.36 | 246.27 | 299.98 | Upgrade |
Other Financing Activities | -43.31 | -8.79 | 24.67 | -87.61 | 500.85 | 495 | Upgrade |
Financing Cash Flow | 231.59 | 294.16 | 172.13 | 425.75 | 1,247 | 994.98 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 39.39 | -15.24 | 6.39 | -7.43 | -9.02 | 4.92 | Upgrade |
Net Cash Flow | 144.67 | 153.77 | -53.67 | 46.4 | 323.11 | -50.58 | Upgrade |
Beginning Cash & Cash Equivalents | 971.19 | 814.88 | 868.56 | 822.15 | 499.05 | 549.63 | Upgrade |
Ending Cash & Cash Equivalents | 1,116 | 968.65 | 814.88 | 868.56 | 822.15 | 499.05 | Upgrade |
Free Cash Flow | -52.09 | -42.59 | 41.95 | -613.33 | -718.07 | -685.32 | Upgrade |
FCF Margin | -2.12% | -1.89% | 2.29% | -59.12% | -85.05% | -139.05% | Upgrade |
Free Cash Flow Per Share | -0.40 | -0.33 | 0.34 | -5.04 | -6.06 | -5.96 | Upgrade |
Levered Free Cash Flow | -292.44 | -383.3 | -303.2 | -851.53 | -400.53 | -610.67 | Upgrade |
Unlevered Free Cash Flow | -182.24 | -328.53 | -140.75 | -756.55 | -755.79 | -778.23 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.